Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$7.55 - $11.25 $1.03 Million - $1.54 Million
-136,766 Reduced 91.16%
13,262 $102,000
Q2 2023

Aug 14, 2023

BUY
$6.94 - $13.99 $1.04 Million - $2.1 Million
150,028 New
150,028 $1.72 Million
Q3 2022

Nov 14, 2022

BUY
$5.57 - $7.47 $490,761 - $658,166
88,108 Added 226.46%
127,014 $752,000
Q2 2022

Aug 08, 2022

SELL
$4.82 - $10.09 $538,688 - $1.13 Million
-111,761 Reduced 74.18%
38,906 $230,000
Q1 2022

May 16, 2022

BUY
$2.75 - $9.44 $414,334 - $1.42 Million
150,667 New
150,667 $1.15 Million
Q4 2021

Mar 03, 2022

SELL
$2.47 - $5.55 $39,690 - $89,182
-16,069 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$2.63 - $4.12 $42,261 - $66,204
16,069 New
16,069 $42,000

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $151M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.